Session » Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

Date: Monday, November 14, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1715

ABT-122, an Immunoglobulin Targeting Both TNF-α and IL-17A, Does Not Provide Significantly Greater Efficacy Compared with Adalimumab in Subjects with Psoriatic Arthritis: Results from Exposure-Response Analyses

9:00AM-11:00AM: Abstract Number: 1737

Adherence to Subcutaneous Biological Therapies Among Inflammatory Arthropaty Patients from a University Hospital

9:00AM-11:00AM: Abstract Number: 1726

An Integrated Safety Data Analysis Across All Phase II and Phase III Clinical Programs for Ustekinumab in Psoriatic Arthritis, Crohn’s Disease, and Psoriasis

9:00AM-11:00AM: Abstract Number: 1734

Apremilast Is Associated with Long-Term DAS-28 (CRP) Remission and Improvements in Skin Disease: Results from a Phase III Study in DMARD/Biologic-Experienced Active Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1680

Apremilast Monotherapy As the First Systemic Treatment in DMARD-Naive Patients with Active Psoriatic Arthritis: 3-Year Treatment Results

9:00AM-11:00AM: Abstract Number: 1711

Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials

9:00AM-11:00AM: Abstract Number: 1732

Articular and Axial Involvement Differences in Psoriatic Arthritis Patients Treated with Golimumab in Canadian Real-World Practice

9:00AM-11:00AM: Abstract Number: 1727

Association Between Biologic Therapies and Major Adverse Cardiac Events or Cardiac Heart Failure in Psoriatic Arthritis or Psoriasis: A Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1686

Association of Early Skin Improvement with ACR Responses Among Biologic DMARD-Naive Psoriatic Arthritic Patients Treated with Ixekizumab

9:00AM-11:00AM: Abstract Number: 1702

Baseline Patient Characteristics Associated with Response to Biologic Therapy in Patients with Psoriatic Arthritis Enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-11:00AM: Abstract Number: 1681

Beneficial Effect of n-3 Polyunsaturated Fatty Acids on Inflammation and Analgesic Use in Psoriatic Arthritis – a Randomised, Double Blind, Placebo-Controlled Trial

9:00AM-11:00AM: Abstract Number: 1735

Canadian Humira Post-Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (Complete-PsA): Interim Analysis

9:00AM-11:00AM: Abstract Number: 1693

Chronic Back Pain in Early Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1725

Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis

9:00AM-11:00AM: Abstract Number: 1739

Comparative Effectiveness of Secukinumab and Adalimumab in Ankylosing Spondylitis As Assessed By Matching-Adjusted Indirect Comparison: An Analysis Based on All Pivotal Phase 3 Clinical Trial Data

9:00AM-11:00AM: Abstract Number: 1728

Comparison of Adherence to Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis and Other Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1723

Composite Psoriatic Disease Activity Index (CPDAI), Defining Remission and Disease Activity States Using Data from Daily Clinical Practice

9:00AM-11:00AM: Abstract Number: 1704

Consistent Safety and Tolerability of Secukinumab over Long-Term Exposure in Patients with Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses

9:00AM-11:00AM: Abstract Number: 1708

Cutaneous Microbiota Features Distinguish Psoriasis from Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1731

Disease Burden and Impact of Certolizumab Pegol Treatment on Workplace and Household Productivity Across Working Age Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis Patients

9:00AM-11:00AM: Abstract Number: 1730

Disease Progression Among Non-Achievers of Minimal Disease Activity in Psa Patients Treated with Infliximab or Golimumab

9:00AM-11:00AM: Abstract Number: 1694

Does Treat to Target or Achieving Remission Improve Radiographic Outcome in Psa?

9:00AM-11:00AM: Abstract Number: 1703

Early Onset of Efficacy with Apremilast Monotherapy in Biologic-Naive Patients with Active Psoriatic Arthritis: A Phase IIIb, Randomized, Controlled Trial

9:00AM-11:00AM: Abstract Number: 1687

Effect of Concomitant Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) on the Efficacy and Safety of Ixekizumab in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1690

Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate to Severe Psoriasis: 52-Week Results

9:00AM-11:00AM: Abstract Number: 1736

Efficacy of TNF Inhibitors in Axial Spondyloarthritis According to the Presence of Objective Signs of Inflammation: A Multicentric Retrospective Study

9:00AM-11:00AM: Abstract Number: 1716

Higher Frequency and Severity of Coronary Plaques on Coronary CT Angiography in Psoriatic Arthritis Patients without Symptoms of Coronary Artery Disease Compared to Controls

9:00AM-11:00AM: Abstract Number: 1683

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-11:00AM: Abstract Number: 1689

Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1688

Ixekizumab Provides Sustained Improvement up to 52 Weeks of Disease Activity As Assessed By Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1698

Late Onset Psoriatic Arthritis in a Longitudinal Cohort: Disease Presentation, Activity over Time and Prognosis

9:00AM-11:00AM: Abstract Number: 1713

Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials

9:00AM-11:00AM: Abstract Number: 1740

Long-Term Improvements in Physical Function of DMARD-Naive and DMARD/Biologic-Experienced Psoriatic Arthritis Patients Treated with Apremilast: Data from a Large Database of 4 Phase III Clinical Trials

9:00AM-11:00AM: Abstract Number: 1696

Minimal Disease Activity Is a Stable Measure of Therapeutic Response in Psoriatic Arthritis Patients Receiving Treatment with Adalimumab

9:00AM-11:00AM: Abstract Number: 1710

Musculoskeletal Symptoms Preceding the Diagnosis of Psoriatic Arthritis – a Qualitative Exploration of the Patient Journey

9:00AM-11:00AM: Abstract Number: 1741

Patients with Active Psoriatic Arthritis Achieving Minimal Disease Activity with Secukinumab Treatment Demonstrate Sustained Improvement of Function and Quality of Life

9:00AM-11:00AM: Abstract Number: 1695

Pharmacological Monitoring of Adalimumab and Etanercept-Treated Psoriatic Arthritis Patients in Predicting Future Treatment Response

9:00AM-11:00AM: Abstract Number: 1720

Predictive Value of Different Tools for Detection of Psoriatic Arthritis in Patients with Psoriasis in Daily Routine Care Using Questionnaires for Diagnosis of Psoriatic Arthritis and Fluorescence-Optical Imaging Technique

9:00AM-11:00AM: Abstract Number: 1722

Predictors of Achieving Remission Among Patients with Psoriatic Arthritis Prescribed TNF Inhibitors

9:00AM-11:00AM: Abstract Number: 1679

Predictors of Persistency with TNFi in Biologic-Experienced Versus Biologic-Naive Psa Patients Enrolled in the Corrona Registry

9:00AM-11:00AM: Abstract Number: 1717

Progression of Radiographic Axial Damage in Patients with Psoriatic Arthritis. Relation with Clinical and Analytical Factors

9:00AM-11:00AM: Abstract Number: 1706

Quality of Life at Baseline in Early Psoriatic Arthritis Related to Disease Domains

9:00AM-11:00AM: Abstract Number: 1709

Randomized, Double-Blind Study Comparing Chs-0214 with Etanercept (Enbrel) in Patients with Psoriasis and Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1699

RAPID3 Near Remission Shows Good Agreement with Minimal Disease Activity Criteria in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1714

Risk of 10-Year Cardiovascular Disease Assessed By Framingham Risk Score Is Similar in Patients with Psoriatic Arthritis and Psoriasis As Assessed By Atherosclerotic Cardiovascular Disease and Framingham Risk Scores

9:00AM-11:00AM: Abstract Number: 1738

Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison

9:00AM-11:00AM: Abstract Number: 1729

Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Infliximab Using a Matching-Adjusted Indirect Comparison

9:00AM-11:00AM: Abstract Number: 1719

Secular Trends in Treatment Patterns for Psoriasis and Psoriatic Arthritis: A Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 1721

Subclinical Atherosclerosis Evolution during 5 Years of Anti-Tnfalpha Treatment in Psoriatic Arthritis Patients: Preliminary Data

9:00AM-11:00AM: Abstract Number: 1733

Sustained Efficacy of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1691

The Comparative Immunogenicity of Biologic Therapy and Its Clinical Relevance in Psoriatic Arthritis: A Systematic Review of the Literature

9:00AM-11:00AM: Abstract Number: 1724

The Effect of Certolizumab Pegol on Skin Manifestations of Psoriatic Arthritis over 4 Years of Treatment

9:00AM-11:00AM: Abstract Number: 1701

The Presence of Depression Might be an Important Determinant of Achieving Minimal Disease Activity State in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1712

The Relationship Between Physical Functioning and Work for People with Psoriatic Arthritis: Results from a Large Real-World Study in 16 Countries

9:00AM-11:00AM: Abstract Number: 1705

The Risk of Fracture Among Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1682

Tnfα Inhibitors Are Associated with Reduced Progression of Carotid Atherosclerotic Plaques By Ultrasound and an Improvement in Aortic Arch Vascular Inflammation By 18-FDG PET/CT in Psoriasis and Psoriatic Arthritis Patients – a Prospective Study from Two Cohorts

9:00AM-11:00AM: Abstract Number: 1700

Treating Psoriatic Arthritis (PsA) to Target: Defining Psoriatic Arthritis Disease Activity Score (PASDAS) That Reflects Disease Activity in Psa

9:00AM-11:00AM: Abstract Number: 1685

Updated Results for All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study

9:00AM-11:00AM: Abstract Number: 1684

Updated Results for Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study

9:00AM-11:00AM: Abstract Number: 1707

Ustekinumab and the Comparative Risk for Acute Myocardial Infarction in Patients with Psoriasis and Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1718

Ustekinumab, Apremilast, TNFi and the Risk for Hospitalized Infection in Patients with Psoriasis and Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1692

Validation of a Two-Question Patient Reported Outcome Measure for Psoriasis

9:00AM-11:00AM: Abstract Number: 1697

Validity of Diagnostic Codes and Point Prevalence of Psoriatic Arthritis in Israel – a Population-Based Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].